7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet
34
Participants partenaires
TERMINÉ
European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,
...ologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenot ...
Voir le projet
29
Participants partenaires
TERMINÉ
New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours (PREDECT)
Date du début: 1 févr. 2011, Date de fin: 30 avr. 2016,
... and AstraZeneca, and the managing entity of IMI JU funding is the University of Helsinki. The team assembles world-class biologists, clinicians and computational scientists from 8 prestigious EU institutes, 3 SMEs and 8 EFPIA members to develop and critically assess models for target validation. The interaction between pharmaceutical and academic participants will be proactive, through postdoc co ...
Voir le projet
23
Participants partenaires
TERMINÉ
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet
38
Participants partenaires
TERMINÉ
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)
Date du début: 1 févr. 2010, Date de fin: 30 sept. 2015,
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Voir le projet
23
Participants partenaires
TERMINÉ
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)
Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,
...s and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive functi ...
Voir le projet
20
Participants partenaires
TERMINÉ
Genomic Instability in Cancer and Precancer (GENICA)
Date du début: 1 janv. 2008, Date de fin: 31 déc. 2010,
"Genomic instability is a characteristic of practically all human cancers. Recent results generated by members of this Consortium suggest that signs of genomic instability are evident from the very beginning of human cancer development, even in precancerous lesions. In these early lesions, the genomic instability affects primarily specific genomic loci, called common fragile sites. Because common ...
Voir le projet